Cargando…

Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT

Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Lena, Balmus, Caroline, Ahmadzadehfar, Hojjat, Essler, Markus, Strunk, Holger, Bundschuh, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620612/
https://www.ncbi.nlm.nih.gov/pubmed/28758969
http://dx.doi.org/10.3390/ph10030068
_version_ 1783267624037122048
author Thomas, Lena
Balmus, Caroline
Ahmadzadehfar, Hojjat
Essler, Markus
Strunk, Holger
Bundschuh, Ralph A.
author_facet Thomas, Lena
Balmus, Caroline
Ahmadzadehfar, Hojjat
Essler, Markus
Strunk, Holger
Bundschuh, Ralph A.
author_sort Thomas, Lena
collection PubMed
description Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by (99m)Tc-MDP bone scan and (68)Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied.
format Online
Article
Text
id pubmed-5620612
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56206122017-10-03 Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT Thomas, Lena Balmus, Caroline Ahmadzadehfar, Hojjat Essler, Markus Strunk, Holger Bundschuh, Ralph A. Pharmaceuticals (Basel) Article Purpose: Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool. The aim of our study was to investigate the difference between bone scan and PSMA-PET/CT for the detection of bone metastases in prostate cancer. Methods: Thirty patients with bone metastases originating from prostate cancer were examined by (99m)Tc-MDP bone scan and (68)Ga-PSMA-PET/CT within an average of 21 days. Bone scans were analyzed visually according to the number of lesions and using the software package ExiniBONE by Exini Diagnostics. PET/CT data was analyzed visually. Numbers of detected lesions were compared for the different methods for the whole patient and for different regions. In addition, results were compared to serum prostate-specific antigen (PSA), alkaline phosphatase (ALP), bone alkaline phosphatase (bALP), pro gastrin releasing peptide (pGRP) and eastern cooperative oncology group (ECOG) performance status. Results: In the bone scans, visual and semiautomatic lesion detection showed similar results with an average of 19.4 and 17.8 detected bone lesion per patient. However, in PSMA-PET/CT, on average double the numbers of lesions (40.0) were detected. The largest differences were found in the thorax and pelvis, which can be explained by the advantages of tomographic imaging. Bland-Altman analysis showed greater differences in patients with large numbers of bone metastases. Conclusion: No significant difference was found when using semiautomatic analysis compared to visual reading for bone scans. Fewer bone metastases were detected in bone scans than in PSMA-PET/CT. However, in none of our patients would the difference have led to clinical consequences. Therefore, it seems that for patients undergoing PSMA-PET/CT, there is no need to perform additional bone scans if the appropriate PET/CT protocols are applied. MDPI 2017-07-31 /pmc/articles/PMC5620612/ /pubmed/28758969 http://dx.doi.org/10.3390/ph10030068 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Thomas, Lena
Balmus, Caroline
Ahmadzadehfar, Hojjat
Essler, Markus
Strunk, Holger
Bundschuh, Ralph A.
Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
title Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
title_full Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
title_fullStr Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
title_full_unstemmed Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
title_short Assessment of Bone Metastases in Patients with Prostate Cancer—A Comparison between (99m)Tc-Bone-Scintigraphy and [(68)Ga]Ga-PSMA PET/CT
title_sort assessment of bone metastases in patients with prostate cancer—a comparison between (99m)tc-bone-scintigraphy and [(68)ga]ga-psma pet/ct
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620612/
https://www.ncbi.nlm.nih.gov/pubmed/28758969
http://dx.doi.org/10.3390/ph10030068
work_keys_str_mv AT thomaslena assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT balmuscaroline assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT ahmadzadehfarhojjat assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT esslermarkus assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT strunkholger assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct
AT bundschuhralpha assessmentofbonemetastasesinpatientswithprostatecanceracomparisonbetween99mtcbonescintigraphyand68gagapsmapetct